BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 2
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) --BeiGene Co.,Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14, 2020.
Oral Presentation:
| Title: | ASPEN: Results of a Phase 3 Randomized Trial Of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM) |
| Abstract #: | S225 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Presenter: | Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece |
Poster Presentations:
| Title: | Updated Results of the ASPEN Trial from a Cohort of Patients with MYD88 Wild-Type Waldenström Macroglobulinemia |
| Abstract #: | EP1180 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece |
| Title: | Three-Year Follow-Up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single Agent Zanubrutinib |
| Abstract #: | EP1168 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Stephen Opat, MBBS, Monash University, Australia |
| Title: | Phase 1/2 Study of Single-Agent Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma |
| Abstract #: | EP1165 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy |
| Title: | Tislelizumab (BGB-A317) for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study |
| Abstract #: | EP1268 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Huiqiang Huang, M.D., Ph.D., Sun Yat-sen University Cancer Center, China |
| Title: | Tislelizumab (BGB-A317) for Relapsed/Refractory Peripheral T-Cell Lymphomas: Safety and Efficacy Results from a Phase 2 Study |
| Abstract #: | EP1235 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Italy |
| Title: | Biomarker Identification in Relapsed/Refractory Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Treated with Zanubrutinib |
| Abstract #: | EP1246 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Haiyan Yang, M.D., Zhejiang Cancer Hospital, China |
| Title: | Zanubrutinib (BGB-3111) in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma |
| Abstract #: | EP1271 |
| Session Title: | Aggressive Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Jianfeng Zhou, M.D., Tongji Medical College, China |
| Title: | Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies |
| Abstract #: | EP1169 |
| Session Title: | Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical |
| Lead Author: | Keshu Zhou, M.D., Henan Cancer Hospital, China |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com
BeiGene Media Contact
Liza Heapes
+1 857-302-5663
media@beigene.com
